Assembly Biosciences Inc./$ASMB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Ticker

$ASMB
Sector
Primary listing

Employees

73

ASMB Metrics

BasicAdvanced
$415M
-
-$5.56
0.65
-

Bulls say / Bears say

Assembly secured a $20.1 million equity investment plus $10 million in accelerated funding from Gilead, extending its cash runway into mid-2026 and bolstering financial stability through key data catalysts(Barron's).
Collaboration revenue with Gilead rose to $9.4 million in Q1 2025 from $5.8 million a year earlier, reflecting increased non-dilutive funding to support R&D programs(SEC 10-Q).
Multiple key clinical readouts are expected throughout 2025, including efficacy, safety and PK data from the ABI-4334 Phase 1b 400 mg cohort in H1 2025 and interim Phase 1b data for ABI-5366 and ABI-1179 in fall 2025, underscoring robust pipeline momentum(SEC 10-K Exhibit 99.1)
Cash, cash equivalents and marketable securities declined from $112.1 million at year-end 2024 to $91.0 million as of March 31, 2025, implying a $21.1 million quarterly cash burn that may pressure resources ahead of key pipeline milestones(GlobeNewswire).
Research and development expenses rose 25% year-over-year to $14.9 million in Q1 2025, further accelerating the company’s burn rate amid pre-commercial stage programs(GlobeNewswire).
All of Assembly Bio’s investigational candidates remain unapproved, with safety and efficacy yet to be established, exposing the company to clinical failure risk before generating any product revenue(GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 25 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ASMB

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs